Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Stomach Neoplasms 2 Multiple Myeloma 2 Mouth Neoplasms 2 Lymphoma 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Carcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Fallopian Tube Neoplasms 1 FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1 Esophageal Neoplasms 1

Interventions

Oxaliplatin 9 Capecitabine 9 Paclitaxel 7 Fluorouracil 7 pembrolizumab 6 Leucovorin 6 Cisplatin 5 zolbetuximab 4 Docetaxel 4 trastuzumab deruxtecan 3 enzalutamide 3 durvalumab 3 cemiplimab 3 Trastuzumab 3 Nivolumab 3 Irinotecan 3 Gemcitabine 3 Albumin-Bound Paclitaxel 3 fludarabine 2 darolutamide 2 atezolizumab 2 Taxes 2 Ramucirumab 2 Radiotherapy, Image-Guided 2 Radiosurgery 2 Pemetrexed 2 Cyclophosphamide 2 Carboplatin 2 130-nm albumin-bound paclitaxel 2 vistusertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × ipatasertib × 90 days × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡